Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5004-5011

  Chevillotte, Meike ^a,b   Ersing, Ina ^a   Mertens, Thomas ^a   Von Einem, Jens ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE;

ANTIVIRAL RESISTANCE; ARTICLE; DATA BASE; DRUG SENSITIVITY; GENOTYPE; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; MUTATION; POLYMORPHISM, GENETIC;

EID: 78649646827     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00259-10     Document Type: Article

References (40)

1. Baldanti, F., M. R. Underwood, S. C. Stanat, K. K. Biron, S. W. Chou, A. Sarasini, E. Silini, and G. Gerna. 1996. Single amino acids changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395. (Pubitemid 26062895)
2. Boeckh, M., and P. Ljungman. 2009. How we treat CMV in hematopoietic cell transplant recipients. Blood 113:5711-5719.
3. Chevillotte, M., J. von Einem, B. M. Meier, F. M. Lin, H. A. Kestler, and T. Mertens. 2010. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 85:318-327.
4. Chevillotte, M., S. Landwehr, L. Linta, G. Frascaroli, A. Luske, C. Buser, T. Mertens, and J. von Einem. 2009. The major tegument protein pp65 of human cytomegalovirus is required for the incorporation of pUL69 and pUL97 into the virus particle and for viral growth in macrophages. J. Virol. 83:2480-2490.
5. Chevillotte, M., A. Schubert, T. Mertens, and J. von Einem. 2009. Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother. 53:3752-3761.
6. Chou, S. W., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39. (Erratum, 190:1202, 2004.)
7. Chou, S. W., N. S. Lurain, A. Weinberg, G.-Y. Cai, P. L. Sharma, C. S. Crumpacker, and Adult AIDS Clinical Trials Group CMV Laboratories. 1999. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob. Agents Chemother. 43:1500-1502.
8. Chou, S. W., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789.
9. Chou, S. W., L. C. van Wechel, H. M. Lichy, and G. Marousek. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49:2710-2715.
10. Chou, S. 2009. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother. 53:81-85.
11. Chou, S., G. Marousek, S. Li, and A. Weinberg. 2008. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J. Clin. Virol. 43:107-109.
12. Chou, S., and G. I. Marousek. 2008. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 82:246-253.
13. Chou, S., G. I. Marousek, L. C. Van Wechel, S. Li, and A. Weinberg. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51:4160-4162.
14. Chou, S., R. C. Miner, and W. L. Drew. 2000. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis. 182:1765-1768.
15. Cihlar, T., M. D. Fuller, and J. M. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936.
16. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
17. Crough, T., and R. Khanna. 2009. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22:76-98.
18. DeLean, A., P. J. Munson, and D. Rodbard. 1978. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235:E97-E102.
19. Drew, W. L., R. C. Miner, G. Marousek, and S. W. Chou. 2006. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37:124-127.
20. Ducancelle, A., S. Alain, F. Petit, M. J. Sanson Le Pors, and M. C. Mazeron. 2007. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet. J. Virol. Methods 141:212-215.
21. Ducancelle, A., G. Champier, S. Alain, F. Petit, M. J. Le Pors, and M. C. Mazeron. 2006. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir. Ther. 11:537-540.
22. Ducancelle, A., J. Gravisse, S. Alain, A.-M. Fillet, F. Petit, M. J. Sanson Le Pors, and M.-C. Mazeron. 2005. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet. J. Virol. Methods 125:145-151.
23. Gilbert, C., and G. Boivin. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883.
24. Ijichi, O., D. Michel, T. Mertens, K. Miyata, and Y. Eizuru. 2002. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antiviral Res. 53:135-142. (Pubitemid 34062833)
25. Kedhar, S. R., and D. A. Jabs. 2007. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes 14:66-71.
26. Lurain, N. S., K. D. Thompson, E. W. Holmes, and S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7146-7152.
27. Marfori, J., M. M. Exner, G. I. Marousek, S. Chou, and C. Gilbert. 2007. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J. Clin. Virol. 38:120-125.
28. Martin, M., A. Azzi, S. X. Lin, and G. Boivin. 2010. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. Antivir. Ther. 15:579-586.
29. Mousavi-Jazi, M., I. Hokeberg, L. Schloss, B. Zweygberg-Wirgart, L. Grillner, A. Linde, and M. Brytting. 2001. Sequence analysis of UL54 and UL97 genes and evaluation of antiviral susceptibility of human cytomegalovirus isolates obtained from kidney allograft recipients before and after treatment. Transpl. Infect. Dis. 3:195-202.
30. Mousavi-Jazi, M., L. Schloss, W. L. Drew, A. Linde, R. C. Miner, J. Harmenberg, B. Wahren, and M. Brytting. 2001. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J. Clin. Virol. 23:1-15.
31. Schreiber, A., G. Härter, A. Schubert, D. Bunjes, T. Mertens, and D. Michel. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10:191-209.
32. Scott, G. M., M. A. Isaacs, F. Zeng, A. M. Kesson, and W. D. Rawlinson. 2004. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J. Med. Virol. 74:85-93.
33. Scott, G. M., A. Weinberg, W. D. Rawlinson, and S. W. Chou. 2007. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 51:89-94.
34. Sinzger, C., G. Hahn, M. Digel, R. Katona, K. L. Sampaio, M. Messerle, H. Hengel, U. Koszinowski, W. Brune, and B. Adler. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89:359-368.
35. Springer, C. L., S. W. Chou, S. Li, R. H. Giller, R. Quinones, J. E. Shira, and A. Weinberg. 2005. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus- infected hematopoietic cell transplant recipients. J. Clin. Microbiol. 43:208-213.
36. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzy, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phoshonylmethoxylalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
37. Sun, H. Y., M. M. Wagener, and N. Singh. 2008. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant. 8:2111-2118.
38. Tischer, B. K., J. von Einem, B. Kaufer, and N. Osterrieder. 2006. Two-step Red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197.
39. Weinberg, A., D. A. Jabs, S. W. Chou, B. K. Martin, N. S. Lurain, M. S. Forman, and C. S. Crumpacker. 2003. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 187:777-784.
40. Ye, L.-B., and E.-S. Huang. 1993. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J. Virol. 67:6339-6347.